Novavax Expands Matrix-M Adjuvant Deals Through Partnership With Sanofi
Novavax, Inc. of Gaithersburg, Maryland is continuing to move away from relying primarily on direct vaccine sales and is instead focusing more heavily on licensing agreements and corporate partnerships. The company recently expanded deals with pharmaceutical giants Pfizer, Inc. and Sanofi SA as it attempts to build a more stable revenue stream following a sharp […]
Novavax Signs Licensing Agreement With Pfizer for Vaccine Adjuvant Technology
Novavax, Inc. and Pfizer, Inc. have signed a licensing arrangement allowing Pfizer access to Novavax’s Matrix-M adjuvant technology to boost immune response to vaccines. The agreement will allow for use in vaccines targeting up to two infectious diseases.1 Novavax’s Matrix-M technology is an aluminum-free adjuvant designed to enhance the immune response in protein-based vaccines such […]
FDA Revokes EUA Status for COVID-19 Shots
The U.S. Department of Health and Human Services (DHHS) has revoked emergency use authorization (EUA) for the COVID-19 shots. The federal government had relied on the EUA status to justify release of the COVID-19 biologicals in December 2020 for public distribution without full licensure by the FDA.1 On Aug. 27, 2025, DHHS Secretary Robert F. […]
CDC Vaccine Advisory Panel Purged
On June 9, 2025, U.S. Secretary of Health and Human Services Robert F. Kennedy, Jr. fired all 17 members of the U.S. Centers for Disease Control and Prevention’s (CDC) committee that makes national vaccine policy—the Advisory Committee on Immunization Practices (ACIP). “A clean sweep is necessary to reestablish public confidence in vaccine science,” Secretary Kennedy […]
FDA Approves Novavax’s COVID-19 Vaccine With Restrictions
On May 16, 2025, the U.S. Food and Drug Administration (FDA) approved licensure of Novavax, Inc.’s Nuvaxovid protein-based COVID-19 vaccine, which has been available in the United States under Emergency Use Authorization (EUA) since July 2022.1 The decision for a full licensure was postponed while the new agency leadership under the current administration conducted a […]
Influenza-COVID Combo Vaccine Trial Halted Over Safety Concerns
The U.S. Food and Drug Administration (FDA) has put a hold on Novavax’s COVID-influenza combination vaccine and standalone influenza vaccines being tested in clinical trials after a participant reported nerve damage following receipt of the experimental vaccine in January 2024.1 Reported symptoms were diagnosed as motor neuropathy, a disease process that can be acquired, hereditary […]